Novel Diet, Drugs, and Gastric Interventions for Gastroparesis
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
This review of the pathophysiological basis for gastroparesis and recent advances in the treatment of patients with gastroparesis shows that there are several novel approaches to advance treatment of gastroparesis including diet, novel prokinetics, interventions on the pylorus, and novel forms of gastric electrical stimulation. The field of gastroparesis is likely to advance with further studies, with the help from a guidance document from the FDA on gastroparesis, and with the recent approval of the stable isotope gastric emptying test to ensure eligibility of participants in multicenter trials. Clinical experience and a formal, randomized, controlled trial provide insights on optimizing dietary interventions in patients with gastroparesis. This review addresses the biological rationale of these different treatments, based on known physiology and pathophysiology of gastric emptying. The novel medications include the motilin agonist, camicinal, 5-HT4 receptor agonists such as velusetrag, and the ghrelin agonist, relamorelin. New approaches target pylorospasm by either stent placement, endoscopic pyloric myotomy or laparoscopic pyloroplasty. These approaches offer the opportunity to achieve more permanent reduction of resistance to flow at the pylorus over the intrapyloric injection of botulinum toxin, which typically has to be repeated every few months if it is efficacious. A novel device, deployed in porcine stomach, involved per-endoscopic electrical stimulation. These promising approaches require formal, randomized, controlled trials and deployment in patients. The presence of concomitant antral hypomotility may be a significant factor in the responsiveness to interventions at the pylorus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Guideline: Management of Gastroparesis
Camilleri, M., Parkman, H. P., Shafi, M. A., Abell, T. L., & Gerson, L. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.373 · Cited by 1,149
Self-citationPyloric dysfunction in diabetics with recurrent nausea and vomiting
Mearin, F., Camilleri, M., & Malagelada, J.-R. (1986) · Gastroenterology · doi:10.1016/0016-5085(86)90262-3 · Cited by 415 · cited 1×
“In general, antral hypomoility is usually present when there is pylorospasm (Figure 2).(19) This phenomenon is also observed under experimental conditions, such as when saline is replaced by hypertonic glucose in the liquid phase of the meal, or by the addition of high concentration of lipid by intraduodenal infusion.”
BackgroundSelf-citationReview article: metoclopramide and tardive dyskinesia
RAO, A. S., & CAMILLERI, M. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04189.x · Cited by 316 · cited 1×
“Metoclopramide received a black box warning from FDA because of the risk of tardive dyskinesia, although the actual prevalence of involuntary movements and especially tardive dyskinesia was probably overestimated, as discussed in detail elsewhere.(32) A novel preparation of metoclopramide is in the form of nasal spray…”
BackgroundSelf-citationEpidemiology, mechanisms, and management of diabetic gastroparesis
Camilleri, M., Bharucha, A. E., & Farrugia, G. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.09.022 · Cited by 287
Watkins, C. C., Sawa, A., Jaffrey, S., Blackshaw, S., Barrow, R. K., Snyder, S. H., & Ferris, C. D. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8273 · Cited by 268 · cited 1×
“There is reduced expression of neuronal nitric oxide synthase in pylorus of nonobese diabetic mice when they develop diabetes; the reduced expression is reversed by insulin treatment.(59) In this model, the gastric emptying delay in both nonobese diabetic and streptozotocin diabetic mice was reversed with the phosphod…”
Olausson, E. A., Störsrud, S., Grundin, H., Isaksson, M., Attvall, S., & Simrén, M. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.453 · Cited by 217 · cited 1×
“However, a randomized, controlled trial has demonstrated that a small particle size diet reduces upper gastrointestinal symptoms (nausea, vomiting, bloating, postprandial fullness, regurgitation, and heartburn) in patients with diabetic gastroparesis.(31)”
BackgroundSzarka, L. A., Camilleri, M., Vella, A., Burton, D., Baxter, K., Simonson, J., & Zinsmeister, A. R. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.01.009 · Cited by 209
Self-citationClinical and Upper Gastrointestinal Motility Features in Systemic Sclerosis and Related Disorders
Weston, S., Thumshirn, M., Wiste, J., & Camilleri, M. (1998) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1998.00334.x · Cited by 186 · cited 1×
“Measurement of gastric emptying does not differentiate neuropathic from myopathic disorders;(11) the distinction requires appraisal for systemic, serologic, or biopsy manifestations of the underlying diseases (eg, features of scleroderma or mitochondrial cytopathy, serum and urine protein electrophoresis, fat or duode…”
BackgroundSelf-citation
Cited by
Diabetic Enteropathy: From Molecule to Mechanism-Based Treatment
Meldgaard, T., Olesen, S. S., Farmer, A. D., Krogh, K., Wendel, A. A., Brock, B., Drewes, A. M., & Brock, C. (2018) · Journal of Diabetes Research · doi:10.1155/2018/3827301 · Cited by 83
“Prokinetics (Table 2) have been widely studied in the context of diabetic gastroparesis and generally shown effect in most studies [77, 79, 80].”
BackgroundPathogenesis and management of diabetic gastroparesis: An updated clinically oriented review
Uppaluri, S., Jain, M. A., Ali, H., Shingala, J., Amin, D., Ajwani, T., Fatima, I., Patel, N., Kaka, N., Sethi, Y., et al. (2024) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2024.102994 · Cited by 14
The role of diet in diabetes gastroparesis treatment: a systematic review and meta-analysis
Lin, D., Wang, H., Ou, Y., Li, L., Zhang, Q., Yan, J., Peng, D., & Peng, S. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1379398 · Cited by 7
“However, patients receive dietary interventions based on physiological principles rather than clinical evidence (17).”
Background
Metadata
- Authors
- Camilleri, M.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2016-08
- Volume
- 14
- Issue
- 8
- Pages
- 1072-1080
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2218052612
- Cited by
- 80
- References
- 8
- FWCI
- 10.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel Diet, Drugs, and Gastric Interventions for Gastroparesis. https://app.cochat.ai/papers/10.1016/j.cgh.2015.12.033
- The paper
- Camilleri, M. (2016). Novel Diet, Drugs, and Gastric Interventions for Gastroparesis. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2015.12.033
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.